Compare EOI & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Current Price
| Metric | EOI | DSGN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 817.2M | 853.8M |
| IPO Year | 2004 | 2021 |
| Metric | EOI | DSGN |
|---|---|---|
| Price | $19.70 | $12.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 55.1K | ★ 663.2K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.04 | $5.28 |
| 52 Week High | $21.44 | $17.25 |
| Indicator | EOI | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 33.60 |
| Support Level | $19.39 | $11.65 |
| Resistance Level | $20.20 | $13.54 |
| Average True Range (ATR) | 0.19 | 0.70 |
| MACD | -0.05 | -0.38 |
| Stochastic Oscillator | 32.93 | 10.39 |
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation. The company's sector allocation includes: Information Technology, Communication Services, Financials, Consumer Discretionary, Healthcare, Industries, Consumer Staples, Energy, Real Estate, and Materials.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.